ストックスクリーナーアプリを入手
2.56
6.91%
-0.19
前日終値:
$2.75
開ける：
$2.74
24時間の取引高:
235.12K
Relative Volume:
0.57
時価総額：
$160.91M
収益：
$13.86M
当期純損益:
$-79.62M
株価収益率:
-1.9945
EPS:
-1.2835
ネットキャッシュフロー:
$-63.51M
1週間 パフォーマンス:
+39.89%
1か月 パフォーマンス:
+50.59%
6か月 パフォーマンス:
-41.42%
1年 パフォーマンス:
+122.61%
1日の値動き範囲:
$2.51
$2.78
1週間の範囲:
$1.82
$2.92
52週間の値動き範囲:
$0.97
$5.55
Pyxis Oncology Inc Stock (PYXS) Company Profile
Compare PYXS vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
2.56 | 172.85M | 13.86M | -79.62M | -63.51M | -1.2835 |
VRTX
Vertex Pharmaceuticals Inc
|
450.85 | 110.45B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
719.44 | 74.73B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
817.17 | 50.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.76 | 38.03B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
314.04 | 32.24B | 5.36B | 287.73M | 924.18M | 2.5229 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-03 | 再開されました | Stifel | Buy |
| 2025-09-04 | 開始されました | Guggenheim | Buy |
| 2024-11-21 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2024-11-08 | 開始されました | Stephens | Overweight |
| 2024-08-08 | 開始されました | Stifel | Buy |
| 2024-05-07 | 再開されました | Jefferies | Buy |
| 2024-02-09 | 開始されました | BTIG Research | Buy |
| 2024-01-23 | 開始されました | Leerink Partners | Outperform |
| 2023-09-05 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-11-02 | 開始されました | BofA Securities | Neutral |
| 2021-11-02 | 開始されました | Credit Suisse | Outperform |
| 2021-11-02 | 開始されました | Jefferies | Buy |
すべてを表示
Pyxis Oncology Inc (PYXS) 最新ニュース
Pyxis Oncology Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView
TradingKey - TradingKey
Pyxis brings in former ImmunoGen dealmaker to advance MICVO - Stock Titan
Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer - Weekly Voice
Wedbush Initiates Pyxis Oncology at Outperform With $6 Price Target - marketscreener.com
Wedbush initiated coverage on Pyxis Oncology with a new price target - Quantisnow
Wedbush Initiates Pyxis Oncology(PYXS.US) With Buy Rating, Announces Target Price $6 - Moomoo
Wedbush initiates coverage of Pyxis Oncology (PYXS) with outperform recommendation - MSN
Pyxis Oncology (PYXS) Price Target Increased by 13.33% to 6.94 - MSN
Short Interest in Pyxis Oncology, Inc. (NASDAQ:PYXS) Drops By 14.7% - MarketBeat
Pyxis Oncology, Inc. Files Amended 8-K/A Report for 2026 with SEC – Company Details, Address, and Nasdaq Listing - Minichart
Pyxis Oncology (PYXS) Management Strategy | Pyxis Oncology posts 15.6% EPS beat, no revenueDebt Analysis - newser.com
[ARS] Pyxis Oncology, Inc. SEC Filing - Stock Titan
Pyxis Oncology | DEFA14A: Others - Moomoo
Pyxis Oncology (NASDAQ: PYXS) details 2026 vote on directors and auditor - Stock Titan
Pyxis Oncology | 8-K/A: Current report (Amendment) - Moomoo
Lara Sullivan exit package at Pyxis Oncology (NASDAQ: PYXS) - Stock Titan
PYXS Pyxis Oncology beats Q4 2025 loss estimates, but shares shed 2.35 percent amid weak investor reaction.EBIT Margin - Newser
Pyxis Oncology (PYXS) Rating Reiterated as Buy by HC Wainwright & Co. | PYXS Stock News - GuruFocus
PYXS Pyxis Oncology Q4 2025 narrower than expected per share loss sparks double digit share price jump today.Weakness Phase - newser.com
PYXS Stock: Analyzing Pyxis Oncology's Market Performance - Bitget
Pyxis Oncology (PYXS) Cantor Global Healthcare Conference 2025 Summary - Quartr
Pyxis Oncology (PYXS) Morgan Stanley 22nd Annual Global Healthcare Conference summary - Quartr
Pyxis Oncology (PYXS) Registration Filing Summary - Quartr
Pyxis Oncology (PYXS) H.C. Wainwright 26th Annual Global Investment Conference summary - Quartr
Pyxis Oncology (PYXS) Proxy Filing Summary - Quartr
Pyxis Oncology (PYXS) Leerink Global Healthcare Conference 2025 Summary - Quartr
Stifel Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Pyxis presents preclinical data on MICVO in head and neck cancer - Investing.com India
Pyxis presents preclinical data on MICVO in head and neck cancer By Investing.com - Investing.com South Africa
Pyxis Oncology to Present New Preclinical Data Showing - GlobeNewswire
Pyxis Oncology (NASDAQ:PYXS) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
PYXS | Pyxis Oncology, Inc. Common Insider Trading - Quiver Quantitative
Growth Value: Will Pyxis Oncology Inc stock benefit from M ARate Cut & Weekly Stock Breakout Alerts - baoquankhu1.vn
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
PYXS Stock Price, Quote & Chart | PYXIS ONCOLOGY INC (NASDAQ:PYXS) - ChartMill
Stock Recap: Can Pyxis Oncology Inc benefit from deglobalization2026 Earnings & Verified Chart Pattern Signals - baoquankhu1.vn
Price Action: Is Pyxis Oncology Inc part of any major index2026 Reactions & Low Drawdown Momentum Ideas - baoquankhu1.vn
Is Pyxis Oncology (PYXS) Stock overvalued relative to peers | Price at $1.46, Up 0.69%Community Buy Alerts - newser.com
Trade Report: Can Pyxis Oncology Inc expand its profit marginsCPI Data & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Is Pyxis Oncology (PYXS) Stock a Buy Now | Price at $1.45, Down 2.03%Community Momentum Stocks - newser.com
Wall Street Zen Downgrades Pyxis Oncology (NASDAQ:PYXS) to Sell - MarketBeat
PYXS Technical Analysis & Stock Price Forecast - Intellectia AI
PYXS SEC FilingsPyxis Oncology, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
PYXS Earnings History & Surprises | EPS & Revenue Results | PYXIS ONCOLOGY INC (NASDAQ:PYXS) - ChartMill
Pyxis Oncology Inc. (PYXS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Pyxis Oncology (PYXS) Receives a Rating Update from a Top Analyst - The Globe and Mail
Pyxis Oncology (NASDAQ:PYXS) Stock Rating Upgraded by Wall Street Zen - marketbeat.com
HC Wainwright Raises Earnings Estimates for Pyxis Oncology - Defense World
Stock Report: Can Pyxis Oncology Inc expand its profit marginsDividend Hike & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Q1 EPS Estimates for Pyxis Oncology Raised by HC Wainwright - MarketBeat
Pyxis Oncology Inc (PYXS) 財務データ
収益
当期純利益
現金流量
EPS
1.76%
1.01%
大文字化:
|
ボリューム (24 時間):